๐
Vitekta
elvitegravir
HIV Infections
๐ซ Withdrawn
โ
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.
What it's used for
Vitekta co-administered with a ritonavir-boosted protease inhibitor and with other antiretroviral agents, is indicated for the treatment of human-immunodeficiency-virus-1 (HIV-1) infection in adults who are infected with HIV-1 without known mutations associated with resistance to elvitegravir.
โ ๏ธ Patient safety
No
Official EMA page
https://www.ema.europa.eu/en/medicines/human/EPAR/vitekta